Ilias Kounis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilias Kounis has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Angus Hann
Department of Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, UK
1 shared publicationAudrey Coilly
Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif, Île-de-France, France
1 shared publication- Audrey Coilly
Centre Hépato-Biliaire, hôpital Paul-Brousse AP-HP, Université Paris-Saclay, Inserm U1193, Paris, France
1 shared publication Bo-Göran Ericzon
Transplantation Surgery, Karolinska Institute, Stockholm, Sweden
1 shared publicationCarmelo Loinaz
HBP and Transplant Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
1 shared publicationCaroline Den Hoed
Gastroenterology and Hepatology, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by Elsevier in SSRN Electronic Journal
Everolimus and the Recurrence of Hepatocellular Carcinoma after liver transplantation: A Nationwide Emulated Target Trial Based on Real-World Data
Background: Hepatocellular carcinoma (HCC) is a major indication for liver transplantation (LT). Post-transplant recurrence affects approximately 15% of patients. Everolimus (EVR), an mTOR inhibitor, can reduce recurrence through antitumor effects; however, supporting data remain heterogeneous. Objective: To evaluate the association between EVR use and HCC recurrence following LT for HCC. Methods: Emulated target trials were conducted using French nationwide administrative health data. The cloning–censoring–weighting approach was applied to estimate the effects of EVR initiation and discontinuation after initiation. The primary outcome was the cumulative incidence of HCC recurrence. The secondary outcome was overall survival. Results: Between 2009 and 2020, 3,670 patients underwent LT for HCC, 958 of whom (26.1%) initiated everolimus within three years of LT. The 5-year HCC recurrence rate was 12.5%. Everolimus initiation within three years of LT was associated with lower HCC recurrence at 5 years (HR 0.75; 95% CI 0.64–0.91) and 10 years (HR 0.77; 95% CI 0.61–0.95) and improved 5-year survival (HR 0.92; 95% CI 0.88–0.94). Among everolimus users, discontinuation increased the HCC recurrence risk at 5 years (HR 1.83; 95% CI 1.77–1.93) and 10 years (HR 1.51; 95% CI 1.29–1.71), with reduced survival at both time points (5 years: HR 1.63; 95% CI 1.55–1.87; 10 years: HR 1.63; 95% CI 1.55–1.87). Everolimus initiation 1 year pre-recurrence improved post-recurrence survival (HR 0.64; 95% CI 0.47–0.87; p = 0.005). Conclusion: Everolimus use after LT for HCC reduces the risk of recurrence and improves survival. Discontinuation increases the risks of recurrence and mortality. These findings support the use of everolimus as a key component of immunosuppression in HCC transplant patients, emphasizing the importance of treatment continuity.
- 26 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEverolimus and the Recurrence of Hepatocellular Carcinoma after liver transplantation: A Nationwide Emulated Target Trial Based on Real-World Data
Background: Hepatocellular carcinoma (HCC) is a major indication for liver transplantation (LT). Post-transplant recurrence affects approximately 15% of patients. Everolimus (EVR), an mTOR inhibitor, can reduce recurrence through antitumor effects; however, supporting data remain heterogeneous. Objective: To evaluate the association between EVR use and HCC recurrence following LT for HCC. Methods: Emulated target trials were conducted using French nationwide administrative health data. The cloning–censoring–weighting approach was applied to estimate the effects of EVR initiation and discontinuation after initiation. The primary outcome was the cumulative incidence of HCC recurrence. The secondary outcome was overall survival. Results: Between 2009 and 2020, 3,670 patients underwent LT for HCC, 958 of whom (26.1%) initiated everolimus within three years of LT. The 5-year HCC recurrence rate was 12.5%. Everolimus initiation within three years of LT was associated with lower HCC recurrence at 5 years (HR 0.75; 95% CI 0.64–0.91) and 10 years (HR 0.77; 95% CI 0.61–0.95) and improved 5-year survival (HR 0.92; 95% CI 0.88–0.94). Among everolimus users, discontinuation increased the HCC recurrence risk at 5 years (HR 1.83; 95% CI 1.77–1.93) and 10 years (HR 1.51; 95% CI 1.29–1.71), with reduced survival at both time points (5 years: HR 1.63; 95% CI 1.55–1.87; 10 years: HR 1.63; 95% CI 1.55–1.87). Everolimus initiation 1 year pre-recurrence improved post-recurrence survival (HR 0.64; 95% CI 0.47–0.87; p = 0.005). Conclusion: Everolimus use after LT for HCC reduces the risk of recurrence and improves survival. Discontinuation increases the risks of recurrence and mortality. These findings support the use of everolimus as a key component of immunosuppression in HCC transplant patients, emphasizing the importance of treatment continuity.
- Open Access
COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study
Objective Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. Design Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. Results From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170). Conclusions Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).
Open AccessCOVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study
Objective Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. Design Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. Results From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170). Conclusions Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).